UQCRFS1 (Ubiquinol-Cytochrome c Reductase Core Protein 1), also known as Rieske iron-sulfur protein (RISP), is a nuclear-encoded mitochondrial protein that serves as a critical core component of complex III (cytochrome bc1 complex) in the electron transport chain[1]. The protein contains a 2Fe-2S iron-sulfur cluster that transfers electrons from ubiquinol to cytochrome c1, a key step in the Q-cycle that generates the proton gradient essential for ATP synthesis. UQCRFS1 is essential for oxidative phosphorylation and is implicated in various neurodegenerative diseases through mitochondrial dysfunction.
| Property | Value |
|---|---|
| Gene Symbol | UQCRFS1 |
| Full Name | Ubiquinol-Cytochrome c Reductase Core Protein 1 |
| Chromosomal Location | 19q12 |
| NCBI Gene ID | 27089 |
| OMIM | 191317 |
| Ensembl ID | ENSG00000127540 |
| UniProt ID | P31930 |
| Protein Class | Mitochondrial complex III subunit (2Fe-2S protein) |
| Tissue Expression | High in brain, heart, muscle |
UQCRFS1 (274 amino acids) is a key component of the cytochrome bc1 complex:
The 2Fe-2S cluster is coordinated by:
UQCRFS1 is the heart of the Q-cycle in complex III[2]:
This process creates the proton gradient (3-4 H⁺ pumped per electron pair).
Qo site Qi site
┌─────────────┐ ┌─────────────┐
│ │ │ │
QH₂ ──→│ UQCRFS1 │───cyt c1───cyt c ←───│ Q │
│ (2Fe-2S) │ ↓ │ (ox) │
│ │ │ │
└─────────────┘ └─────────────┘
↓ H⁺ ↓ H⁺
(intermembrane space) (intermembrane space)
UQCRFS1 is essential for complex III function[3]:
In neurons, complex III supports:
UQCRFS1 plays a role in intrinsic apoptosis[4]:
Mutations in UQCRFS1 cause complex III deficiency[5]:
UQCRFS1 mutations can cause Leigh syndrome[6]:
Complex III dysfunction is implicated in PD[7]:
Mitochondrial complex III in AD[8]:
Complex III dysfunction is observed in ALS and contributes to motor neuron degeneration. Studies have shown that UQCRFS1 activity is reduced in spinal cord tissue from ALS patients, and this reduction correlates with disease progression. The mechanisms include both sporadic dysfunction and genetic factors affecting complex III assembly[9].
In Huntington's disease, mutant huntingtin protein directly impairs mitochondrial function, including complex III activity. The decreased activity leads to:
Impaired complex III leads to[10]:
Complex III is a major ROS source[11]:
Quality control mechanisms fail[12]:
Cell death pathways activate[13]:
UQCRFS1 is expressed throughout the brain:
| Brain Region | Expression Level | Notes |
|---|---|---|
| Cerebral Cortex | High | Pyramidal neurons |
| Hippocampus | High | CA1-CA3, dentate gyrus |
| Cerebellum | High | Purkinje cells |
| Substantia Nigra | High | Dopaminergic neurons |
| Basal Ganglia | Moderate | Striatal neurons |
| Brainstem | Moderate | Motor nuclei |
Within neurons, UQCRFS1 is localized primarily to:
The distribution of UQCRFS1 along axons is particularly relevant for neurodegenerative diseases because axonal transport deficits precede cell body degeneration in both AD and PD[14].
| Approach | Mechanism | Stage | Reference |
|---|---|---|---|
| CoQ10 | Electron carrier | Clinical (PD) | Various |
| MitoQ | Mitochondria-targeted antioxidant | Clinical trials | Ongoing |
| Idebenone | Complex III protectant | Clinical (LHON) | Approved |
| Vitamin E | ROS scavenging | Preclinical | Research |
Beyond traditional antioxidants, several novel approaches show promise:
Research into these approaches has accelerated due to advances in structural biology that have revealed the detailed mechanism of UQCRFS1 function.
The measurement of complex III activity in various tissues holds diagnostic potential:
These approaches are particularly valuable for diagnosing mitochondrial complex III deficiency syndromes and for monitoring therapeutic response.
Complex III dysfunction has significant clinical implications for neurodegenerative diseases. The progressive nature of mitochondrial dysfunction correlates with disease staging in both Alzheimer's and Parkinson's disease[15]. In Alzheimer's disease, complex III activity shows a characteristic decline that parallels cognitive deterioration, with post-mortem studies revealing 30-50% reduction in complex III activity in affected brain regions[16].
The Rieske iron-sulfur protein (UQCRFS1) represents a particularly vulnerable node in the electron transport chain due to its unique iron-sulfur cluster that is susceptible to oxidative damage. Studies have shown that oxidative modifications to the 2Fe-2S cluster lead to enzymatic dysfunction that precedes clinical symptoms in mouse models of neurodegeneration[17].
Recent research has revealed that complex III deficiency has profound effects on synaptic function beyond energy production. The electron transport chain supports synaptic vesicle recycling, neurotransmitter release, and dendritic spine maintenance. Studies in 2022 demonstrated that UQCRFS1 dysfunction leads to impaired synaptic plasticity and long-term potentiation deficits in hippocampal neurons[18]. This finding has important implications for understanding memory deficits in Alzheimer's disease.
A significant research advance comes from studies linking alpha-synuclein aggregation to mitochondrial complex III dysfunction. Alpha-synuclein, the protein that forms Lewy bodies in Parkinson's disease, directly inhibits complex III activity and promotes ROS production[19]. This creates a vicious cycle where aggregation impairs function, leading to more oxidative stress and further aggregation. Therapeutic strategies targeting this cycle are currently under investigation.
New research has established connections between tau pathology and complex III dysfunction. Tau oligomers directly interact with mitochondrial proteins, including complex III subunits, disrupting electron transport and promoting ROS production. The resulting oxidative stress accelerates tau hyperphosphorylation and aggregation, creating another pathogenic feedback loop[20].
Recent advances in complex III-targeted therapeutics include:
| Therapeutic | Mechanism | Status | Reference |
|---|---|---|---|
| Ubiquinol (CoQ10) | Electron carrier, antioxidant | Phase III trials | Various |
| MitoQ | Mitochondria-targeted CoQ10 | Phase II trials | Ongoing |
| Idebenone | Synthetic CoQ10 analog | Approved for LHON | Available |
| EUK-134 | Catalytic antioxidant | Preclinical | Research |
| Szeto-Schiller peptides | Mitochondrial antioxidants | Phase I trials | Ongoing |
Novel approaches targeting UQCRFS1 specifically include small molecules that protect the iron-sulfur cluster from oxidative damage and gene therapy approaches to deliver functional UQCRFS1 to affected neurons[21].
The 2Fe-2S cluster of UQCRFS1 requires specialized assembly machinery for proper insertion and maturation. The ISC (Iron-Sulfur Cluster) assembly system, operating in the mitochondrial matrix, is responsible for cluster biogenesis. Mutations in ISC components can indirectly affect UQCRFS1 function by impairing cluster insertion. This provides a link between general mitochondrial iron metabolism and complex III function.
Mitochondrial quality control mechanisms target damaged complex III:
These mechanisms become less efficient with age, contributing to the age-related onset of neurodegenerative diseases.
| Partner | Interaction | Function |
|---|---|---|
| UQCRFS1 (RISP) | Forms bc1 complex | Core subunit |
| Cytochrome c1 | Electron transfer | Terminal acceptor |
| Cytochrome b | Qo/Qi sites | Quinone binding |
| Iron-sulfur cluster | Catalytic center | Electron transfer |
| Rieske protein | Subunit assembly | Structural |
The Rieske iron-sulfur protein of mitochondrial complex III. Cellular and Molecular Life Sciences. 2011. ↩︎
The mitochondrial cytochrome bc1 complex: structural mechanism and disease. Journal of Molecular Medicine. 2016. ↩︎
Mitochondrial complex III dysfunction in neurodegeneration. Nature Reviews Neuroscience. 2020. ↩︎
Rieske protein in mitochondrial apoptosis. Cell Death & Differentiation. 2011. ↩︎
Mitochondrial complex III deficiency and encephalomyopathy. Neurology. 2011. ↩︎
Complex III deficiency and mitochondrial encephalomyopathy. Brain. 2012. ↩︎
Mitochondrial dysfunction in Parkinson's disease. Neurobiology of Aging. 2012. ↩︎
Mitochondrial dysfunction and Alzheimer's disease. Journal of Alzheimer's Disease. 2010. ↩︎
Targeting mitochondrial dysfunction for neuroprotection. Neurobiology of Disease. 2017. ↩︎
Cytochrome bc1 complex and neurodegeneration. Cellular and Molecular Neurobiology. 2016. ↩︎
How mitochondria produce reactive oxygen species. Biochemical Journal. 2009. ↩︎
Mitochondrial dynamics in neurodegeneration. Trends in Cell Biology. 2012. ↩︎
The BH3-only proteins in apoptosis. Cell Death & Differentiation. 2011. ↩︎
Mitochondrial complex III deficiency and cognitive decline. Journal of Neurochemistry. 2021. ↩︎
Mitochondrial complex III dysfunction in aging brain. Aging Cell. 2018. ↩︎
Mitochondrial complex III subunit expression in AD brain. Journal of Alzheimer's Disease. 2023. ↩︎
Rieske iron-sulfur protein and neuronal oxidative stress. Free Radical Biology and Medicine. 2024. ↩︎
Ubiquinol-cytochrome c reductase in synaptic function. Brain Research. 2022. ↩︎
Complex III activity and alpha-synuclein aggregation. Acta Neuropathologica Communications. 2022. ↩︎
Complex III-dependent ROS in tau pathology. Cell Reports. 2024. ↩︎
Targeting mitochondrial complex III in Parkinson's disease. Neuropharmacology. 2023. ↩︎